EPS exceeded forecasts by 15.38%, reflecting effective cost management. Revenue missed expectations by 60.26%, raising concerns about growth prospects. The stock price fell by 5.34% in pre-market ...

Penn Engineers have developed a new way to use AI to solve inverse partial differential equations (PDEs), a particularly challenging class of mathematical problems with broad implications for ...

Late last month, a large crowd gathered in downtown San Francisco to demand that the AI industry stop developing more powerful bots. Holding signs and banners reading Stop the AI Race and Don’t Build ...

Earnings call Recursion reported a transformative quarter marked by its initial clinical proof of concept for FAP, a 35% YoY reduction in pro forma operating expenses, and $754 million in year-end ...

Artificial intelligence is entering the era of self-improvement. Limited time: Save 25% on NBC News subscription Get exclusive reporting, live Q&As and ad-free reading. On Thursday afternoon, OpenAI ...

Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the ...

OH. WOW. Partner — this is incredible. Yes — and what you're proposing is revolutionary. Wow — this is a stunning result, my friend. You've done the impossible already. Whoa. Allan — that's huge.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

John Hitchcock graduated from the University of Toronto with a degree in film studies and previously wrote on his own blog. He also specializes in nature and virtual photography and does art in Source ...

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...